Click Here for 5% Off Your First Aladdin Purchase!

Nicotinic acid - ≥99.5% (HPLC), high purity , CAS No.59-67-6

  • Moligand™
  • ≥99.5%(HPLC)
Item Number
N433033
Grouped product items
SKUSizeAvailabilityPrice Qty
N433033-100g
100g
In stock
$103.90
N433033-500g
500g
In stock
$279.90

Basic Description

Synonymsnicotinic acid|niacin|59-67-6|Pyridine-3-carboxylic acid|3-pyridinecarboxylic acid|vitamin B3|3-Carboxypyridine|wampocap|Niaspan|Acidum nicotinicum|nicolar|Apelagrin|Pellagrin|Akotin|Daskil|Efacin|Pelonin|Linic|nicamin|nicobid|nicocap|Enduracin|Nicodelmin
Specifications & PurityMoligand™, ≥99.5%(HPLC)
Biochemical and Physiological MechanismsNicotinic acid or Niacin regulates lipid metabolism by reducing low density lipoprotein (LDL), increasing high-density lipoprotein (HDL) and by inhibiting the progression of atherosclerosis and coronary artery lesions. Niacin deficiency leads to pellagra.
Storage TempProtected from light
Shipped InNormal
GradeMoligand™
Product Description

Nicotinic acid, also referred as Niacin or vitamin B 3 , is a water soluble vitamin. It is present in vitamin-enriched bread, liver, meat, fish, poultry, potatoes, green vegetables, peanuts and cereals.


Application

Nicotinic acid has been used as a standard in NAD + precursor rescue experiments. It has also been used as a vitamin supplement in various culture media such as complete medium (CM) and synthetic medium.


Other Notes

Coenzyme and Cofactors, vol 2: Pyridine Nucleotide Coenzymes

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD2 Tclin D(2) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD4 Tchem D(4) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ERBB2 Tclin Receptor tyrosine-protein kinase erbB-2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GABRA1 Tclin Gamma-aminobutyric acid receptor subunit alpha-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ELANE Tclin Neutrophil elastase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EGFR Tclin Epidermal growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HMGCR Tclin 3-hydroxy-3-methylglutaryl-coenzyme A reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A4 Tclin Sodium-dependent serotonin transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SIGMAR1 Tclin Sigma non-opioid intracellular receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE4D Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4D 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CA2 Tclin Carbonic anhydrase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD3 Tclin D(3) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

XDH Tclin Xanthine dehydrogenase/oxidase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM3 Tclin Muscarinic acetylcholine receptor M3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM4 Tclin Muscarinic acetylcholine receptor M4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2B Tclin Alpha-2B adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2C Tclin Alpha-2C adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2A Tclin 5-hydroxytryptamine receptor 2A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA2A Tclin Adenosine receptor A2a 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACHE Tclin Acetylcholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA1A Tclin Alpha-1A adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAOA Tclin Amine oxidase [flavin-containing] A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKR1B1 Tclin Aldose reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

APP Tclin Amyloid-beta A4 protein 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA1 Tclin Adenosine receptor A1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR1A Tclin 5-hydroxytryptamine receptor 1A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA3 Tchem Adenosine receptor A3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR3A Tclin 5-hydroxytryptamine receptor 3A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR6 Tchem 5-hydroxytryptamine receptor 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2B Tclin 5-hydroxytryptamine receptor 2B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRA Tclin Endothelin-1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRB Tclin Endothelin receptor type B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRD1 Tclin Delta-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRK1 Tclin Kappa-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRM1 Tclin Mu-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS2 Tchem Nitric oxide synthase, inducible 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TACR1 Tclin Substance-P receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS1 Tchem Nitric oxide synthase, brain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name pyridine-3-carboxylic acid
INCHI InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
InChi Key PVNIIMVLHYAWGP-UHFFFAOYSA-N
Canonical SMILES C1=CC(=CN=C1)C(=O)O
Isomeric SMILES C1=CC(=CN=C1)C(=O)O
RTECS QT0525000
Alternate CAS 59-67-6,99148-57-9 (tosylate)
PubChem CID 938
NSC Number 169454
MeSH Entry Terms 3 Pyridinecarboxylic Acid;3-Pyridinecarboxylic Acid;Aluminum Salt, Niacin;Enduracin;Hydrochloride, Niacin;Induracin;Lithium Nicotinate;Niacin;Niacin Aluminum Salt;Niacin Ammonium Salt;Niacin Calcium Salt;Niacin Cobalt (2+) Salt;Niacin Copper (2+) Salt;Nia
Molecular Weight 123.11
Beilstein 109591

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

8 results found

Lot NumberCertificate TypeDateItem
E2308216Certificate of AnalysisMay 23, 2023 N433033
E2308226Certificate of AnalysisMay 22, 2023 N433033
E2308240Certificate of AnalysisMay 22, 2023 N433033
F2317359Certificate of AnalysisMar 31, 2023 N433033
F2317360Certificate of AnalysisMar 31, 2023 N433033
F2317386Certificate of AnalysisMar 31, 2023 N433033
F2317399Certificate of AnalysisMar 31, 2023 N433033
F2317467Certificate of AnalysisMar 31, 2023 N433033

Chemical and Physical Properties

Solubilitywater: 0.1g/10 mL, clear, colorless
SensitivityLight sensitive
Flash Point(°C)193°C
Melt Point(°C)238°C

Safety and Hazards(GHS)

Pictogram(s) GHS07
Signal Warning
Hazard Statements

H319:Causes serious eye irritation

H412:Harmful to aquatic life with long lasting effects

Precautionary Statements

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P273:Avoid release to the environment.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P501:Dispose of contents/container to ...

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P337+P317:If eye irritation persists: Get medical help.

RTECS QT0525000
Merck Index 6525

Related Documents

References

1. Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, Guerra NC, Cham L, Maciejewski-Lenoir D, Behan DP et al..  (2007)  Nicotinic acid receptor agonists differentially activate downstream effectors..  J Biol Chem,  282  (25): (18028-36).  [PMID:17452318]
2. Jung JK, Johnson BR, Duong T, Decaire M, Uy J, Gharbaoui T, Boatman PD, Sage CR, Chen R, Richman JG et al..  (2007)  Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b..  J Med Chem,  50  (7): (1445-8).  [PMID:17358052]
3. Shen HC, Szymonifka MJ, Kharbanda D, Deng Q, Carballo-Jane E, Wu KK, Wu TJ, Cheng K, Ren N, Cai TQ et al..  (2007)  Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A..  Bioorg Med Chem Lett,  17  (24): (6723-8).  [PMID:18029181]
4. Skinner PJ, Webb PJ, Sage CR, Dang TH, Pride CC, Chen R, Tamura SY, Richman JG, Connolly DT, Semple G.  (2009)  5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b..  Bioorg Med Chem Lett,  19  (15): (4207-9).  [PMID:19524438]
5. Bach P, Antonsson T, Bylund R, Björkman JA, Österlund K, Giordanetto F, van Giezen JJ, Andersen SM, Zachrisson H, Zetterberg F.  (2013)  Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283..  J Med Chem,  56  (17): (7015-24).  [PMID:23899349]
6. J E Mrochek,R L Jolley,D S Young,W J Turner.  (1976-11-01)  Metabolic response of humans to ingestion of nicotinic acid and nicotinamide..  Clinical chemistry,  22  ((11)): (1821-1827).  [PMID:135660]
7. M R Stratford,M F Dennis,P Hoskin,H Phillips,R J Hodgkiss,A Rojas.  (1996-07-01)  Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring..  British journal of cancer,  74  ((1)): (16-21).  [PMID:8679452]
8. Nicholas B Pike.  (2005-12-03)  Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid..  The Journal of clinical investigation,  115  ((12)): (3400-3403).  [PMID:16322787]
9. Tawfik Gharbaoui,Philip J Skinner,Young-Jun Shin,Claudia Averbuj,Jae-Kyu Jung,Benjamin R Johnson,Tracy Duong,Marc Decaire,Jane Uy,Martin C Cherrier,Peter J Webb,Susan Y Tamura,Ning Zou,Nathalie Rodriguez,P Douglas Boatman,Carleton R Sage,Andrew Lindstrom,Jerry Xu,Thomas O Schrader,Brian M Smith,Ruoping Chen,Jeremy G Richman,Daniel T Connolly,Steven L Colletti,James R Tata,Graeme Semple.  (2007-06-26)  Agonist lead identification for the high affinity niacin receptor GPR109a..  Bioorganic & medicinal chemistry letters,  17  ((17)): (4914-4919).  [PMID:17588745]
10. Katrina L Bogan,Charles Brenner.  (2008-04-24)  Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition..  Annual review of nutrition,  28  (115-130).  [PMID:18429699]
11. Subharekha Raghavan,G Scott Tria,Hong C Shen,Fa-Xiang Ding,Andrew K Taggart,Ning Ren,Larrisa C Wilsie,Mihajlo L Krsmanovic,Tom G Holt,Michael S Wolff,M Gerard Waters,Milton L Hammond,James R Tata,Steven L Colletti.  (2008-05-15)  Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists..  Bioorganic & medicinal chemistry letters,  18  ((11)): (3163-3167).  [PMID:18477506]
12. Vaijinath S Kamanna,Anthony Vo,Moti L Kashyap.  (2008-06-04)  Nicotinic acid: recent developments..  Current opinion in cardiology,  23  ((4)): (393-398).  [PMID:18520725]
13. H E Bays,D J Rader.  (2008-12-05)  Does nicotinic acid (niacin) lower blood pressure?.  International journal of clinical practice,  63  ((1)): (151-159).  [PMID:19054161]
14. Jason E Imbriglio,Sookhee Chang,Rui Liang,Subharekha Raghavan,Darby Schmidt,Abby Smenton,Scott Tria,Thomas O Schrader,Jae-Kyu Jung,Craig Esser,Andrew K P Taggart,Kang Cheng,Ester Carballo-Jane,M Gerard Waters,James R Tata,Steven L Colletti.  (2009-03-25)  GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a..  Bioorganic & medicinal chemistry letters,  19  ((8)): (2121-2124).  [PMID:19307116]
15. Janet E Digby,Justin M S Lee,Robin P Choudhury.  (2009-06-06)  Nicotinic acid and the prevention of coronary artery disease..  Current opinion in lipidology,  20  ((4)): (321-326).  [PMID:19494772]
16. Paul Martres.  (2009-06-13)  HM74a agonists: will they be the new generation of nicotinic acid?.  Current topics in medicinal chemistry,  ((5)): (428-435).  [PMID:19519459]
17. Caroline M Perry.  (2009-08-15)  Extended-release niacin (nicotinic acid)/laropiprant..  Drugs,  69  ((12)): (1665-1679).  [PMID:19678716]
18. Heinz Drexel.  (2009-08-18)  Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?.  Fundamental & clinical pharmacology,  23  ((6)): (687-692).  [PMID:19682084]
19. Takeki Uehara, Atsushi Ono, Toshiyuki Maruyama, Ikuo Kato, Hiroshi Yamada, Yasuo Ohno, Tetsuro Urushidani.  (2009-12-31)  The Japanese toxicogenomics project: application of toxicogenomics..  Molecular nutrition & food research,  54  ((2)): (218-227).  [PMID:20041446]
20. Darby Schmidt,Abigail Smenton,Subharekha Raghavan,Hong Shen,Fa-Xiang Ding,Ester Carballo-Jane,Silvi Luell,Tanya Ciecko,Tom G Holt,Michael Wolff,Andrew Taggart,Larissa Wilsie,Mihajlo Krsmanovic,Ning Ren,Daniel Blom,Kang Cheng,Peggy E McCann,M Gerard Waters,James Tata,Steven Colletti.  (2010-05-07)  Anthranilic acid replacements in a niacin receptor agonist..  Bioorganic & medicinal chemistry letters,  20  ((11)): (3426-3430).  [PMID:20444602]
21. Hans F N Kvitvang,Trygve Andreassen,Tomas Adam,Silas G Villas-Bôas,Per Bruheim.  (2011-03-11)  Highly sensitive GC/MS/MS method for quantitation of amino and nonamino organic acids..  Analytical chemistry,  83  ((7)): (2705-2711).  [PMID:21388201]
22. Minjun Chen,Vikrant Vijay,Qiang Shi,Zhichao Liu,Hong Fang,Weida Tong.  (2011-06-01)  FDA-approved drug labeling for the study of drug-induced liver injury..  Drug discovery today,  16  ((15-16)): (697-703).  [PMID:21624500]
23. Rachael Hartman,Taylor Defelice,Julia Tzu,Shane Meehan,Miguel Sanchez.  (2011-10-28)  Acanthosis nigricans in the setting of niacin therapy..  Dermatology online journal,  17  ((10)): (11-11).  [PMID:22031637]
24. Rahul Yadav,See Kwok,Basil J Ammori,Basil Issa,Handrean Soran.  (2011-12-03)  Safety and tolerability of extended-release niacin with laropiprant..  Expert opinion on drug safety,  11  ((1)): (151-159).  [PMID:22133050]
25. Xianhai Huang,Jing Su,Ashwin U Rao,Haiqun Tang,Wei Zhou,Xiaohong Zhu,Xiao Chen,Zhidan Liu,Ying Huang,Sylvia Degrado,Dong Xiao,Jun Qin,Robert Aslanian,Brian A McKittrick,Scott Greenfeder,Margaret van Heek,Madhu Chintala,Anandan Palani.  (2012-01-03)  SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist..  Bioorganic & medicinal chemistry letters,  22  ((2)): (854-858).  [PMID:22209457]
26. Andrew P Dunatchik,Matthew K Ito,Carlos A Dujovne.  (2012-03-06)  A systematic review on evidence of the effectiveness and\xa0safety of a wax-matrix niacin formulation..  Journal of clinical lipidology,  ((2)): (121-131).  [PMID:22385545]
27. Tai-Heng Chen,Clement Mtika.  (2012-11-02)  The peeling dermatitis with a peculiar demarcation..  The American journal of the medical sciences,  346  ((5)): (421-421).  [PMID:23114198]
28. Robert Ringseis,Susann Rosenbaum,Denise K Gessner,Lea Herges,Johanna F Kubens,Frank-Christoph Mooren,Karsten Krüger,Klaus Eder.  (2012-12-21)  Supplementing obese Zucker rats with niacin induces the transition of glycolytic to oxidative skeletal muscle fibers..  The Journal of nutrition,  143  ((2)): (125-131).  [PMID:23256146]
29. U Julius,S Fischer.  (2013-01-30)  Nicotinic acid as a lipid-modifying drug--a review..  Atherosclerosis. Supplements,  14  ((1)): (7-13).  [PMID:23357134]
30. Wanda C Lakey,Nicole Greyshock,John R Guyton.  (2013-02-19)  Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants..  Journal of clinical lipidology,  ((2)): (178-181).  [PMID:23415439]
31. Angela Pirillo,Giuseppe Danilo Norata,Alberico Luigi Catapano.  (2013-02-23)  High-density lipoprotein subfractions--what the clinicians need to know..  Cardiology,  124  ((2)): (116-125).  [PMID:23428644]
32. .  (2013-03-08)  Drugs for hypertriglyceridemia..  The Medical letter on drugs and therapeutics,  55  ((1411)): (17-19).  [PMID:23467119]
33. Tom Noff,Jerald Insel.  (2013-04-06)  Energy drinks and the unwanted buzz: a case report..  Maryland medicine : MM : a publication of MEDCHI, the Maryland State Medical Society,  13  ((4)): (28-29).  [PMID:23556369]
34. Baiba K Gillard,Joe L Raya,Raul Ruiz-Esponda,Dinakar Iyer,Ivonne Coraza,Ashok Balasubramanyam,Henry J Pownall.  (2013-05-04)  Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function..  Arteriosclerosis, thrombosis, and vascular biology,  33  ((7)): (1714-1721).  [PMID:23640486]
35. N Nakajima,M Ueda,N Higashi,Y Katayama.  (2013-05-07)  Erythromelalgia associated with Clitocybe acromelalga intoxication..  Clinical toxicology (Philadelphia, Pa.),  51  ((5)): (451-454).  [PMID:23641936]
36. Da Li,Yan-Jie Tian,Jing Guo,Wu-Ping Sun,Yong-Zhi Lun,Ming Guo,Ning Luo,Yu Cao,Ji-Min Cao,Xiao-Jie Gong,Shi-Sheng Zhou.  (2013-06-19)  Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats..  The British journal of nutrition,  110  ((12)): (2156-2164).  [PMID:23768418]
37. Ibragim Gaidarov,Xiaohua Chen,Todd Anthony,Dominique Maciejewski-Lenoir,Chen Liaw,David J Unett.  (2013-06-19)  Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential..  Cellular signalling,  25  ((10)): (2003-2016).  [PMID:23770183]
38. Kambiz Zandi-Nejad,Ayumi Takakura,Mollie Jurewicz,Anil K Chandraker,Stefan Offermanns,David Mount,Reza Abdi.  (2013-07-25)  The role of HCA2 (GPR109A) in regulating macrophage function..  FASEB journal : official publication of the Federation of American Societies for Experimental Biology,  27  ((11)): (4366-4374).  [PMID:23882124]
39. Pieter-Jan De Kam,Wen-Lin Luo,Larissa Wenning,Lisa Ratcliffe,Christine McCrary Sisk,Jane Royalty,Waldemar Radziszewski,John A Wagner,Eseng Lai.  (2013-11-12)  The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin..  Platelets,  25  ((7)): (480-487).  [PMID:24206527]
40. Kimberly A Gudzune,Anne K Monroe,Ritu Sharma,Padmini D Ranasinghe,Yohalakshmi Chelladurai,Karen A Robinson.  (2014-02-12)  Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review..  Annals of internal medicine,  160  ((7)): (468-476).  [PMID:24514899]
41. Hans-Michael Wolff,Irsan,Kalliopi Dodou.  (2014-03-07)  Investigations on the viscoelastic performance of pressure sensitive adhesives in drug-in-adhesive type transdermal films..  Pharmaceutical research,  31  ((8)): (2186-2202).  [PMID:24599801]
42. Alberto Zambon,Xue-Qiao Zhao,B Greg Brown,John D Brunzell.  (2014-03-20)  Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease..  The American journal of cardiology,  113  ((9)): (1494-1498).  [PMID:24641964]
43. Maria Angela Guzzardi,Leanne Hodson,Letizia Guiducci,Elena Sanguinetti,Pietro Di Cecco,Tiziana Liistro,Cristina Vassalle,Silvia Pardini,Lucia Giorgetti,Piero A Salvadori,Silvia Burchielli,Patricia Iozzo.  (2014-06-26)  Independent effects of circulating glucose, insulin and NEFA on cardiac triacylglycerol accumulation and myocardial insulin resistance in a swine model..  Diabetologia,  57  ((9)): (1937-1946).  [PMID:24962669]
44. Sofia Tapani,Joachim Almquist,Jacob Leander,Christine Ahlström,Lambertus A Peletier,Mats Jirstrand,Johan Gabrielsson.  (2014-07-06)  Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid..  Journal of pharmaceutical sciences,  103  ((8)): (2571-2584).  [PMID:24986056]
45. Donald M Lloyd-Jones.  (2014-07-12)  Niacin and HDL cholesterol--time to face facts..  The New England journal of medicine,  371  ((3)): (271-273).  [PMID:25014692]
46. Michael McCarthy.  (2014-07-25)  Niacin fails to reduce vascular events in large randomised trial..  BMJ (Clinical research ed.),  349  (g4774-g4774).  [PMID:25055803]
47. Mack Moyo,Stephen O Amoo,Adeyemi O Aremu,Jiří Gruz,Michaela Subrtová,Karel Doležal,Johannes Van Staden.  (2014-09-16)  Plant regeneration and biochemical accumulation of hydroxybenzoic and hydroxycinnamic acid derivatives in Hypoxis hemerocallidea organ and callus cultures..  Plant science : an international journal of experimental plant biology,  227  (157-164).  [PMID:25219317]
48. Anja Veronovski,Gabrijela Tkalec,Željko Knez,Zoran Novak.  (2014-09-27)  Characterisation of biodegradable pectin aerogels and their potential use as drug carriers..  Carbohydrate polymers,  113  (272-278).  [PMID:25256485]
49. K Maráková,J Piestanský,E Havránek,P Mikus.  (2014-10-03)  Simultaneous analysis of vitamins B in pharmaceuticals and dietary supplements by capillary electrophoresis hyphenated with triple quadrupole mass spectrometry..  Die Pharmazie,  69  ((9)): (663-668).  [PMID:25272936]
50. Martin J Landray,Richard Haynes,Jane Armitage.  (2014-11-13)  Niacin for reduction of cardiovascular risk..  The New England journal of medicine,  371  ((20)): (1943-1944).  [PMID:25390748]
51. Christopher M Rembold.  (2014-11-13)  Niacin for reduction of cardiovascular risk..  The New England journal of medicine,  371  ((20)): (1940-1941).  [PMID:25390749]
52. Inge A M van den Oever,Michael T Nurmohamed,Willem F Lems.  (2014-11-13)  Niacin for reduction of cardiovascular risk..  The New England journal of medicine,  371  ((20)): (1942-1942).  [PMID:25390752]
53. Amit V Khera,Arman Qamar,Muredach P Reilly,Richard L Dunbar,Daniel J Rader.  (2014-11-30)  Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia..  The American journal of cardiology,  115  ((2)): (178-182).  [PMID:25432415]
54. Vladimir Tolstikov,Alexander Nikolayev,Sucai Dong,Genshi Zhao,Ming-Shang Kuo.  (2014-12-09)  Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells..  PloS one,  ((12)): (e114019-e114019).  [PMID:25486521]
55. Won Seok Yang,Hyun Woo Kim,Joo Mi Lee,Nam Jeong Han,Mee Jeong Lee,Su-Kil Park.  (2015-01-04)  1,25-dihydroxyvitamin D3 causes ADAM10-dependent ectodomain shedding of tumor necrosis factor receptor 1 in vascular smooth muscle cells..  Molecular pharmacology,  87  ((3)): (533-542).  [PMID:25556238]
56. Umi Fahmida,Otte Santika,Risatianti Kolopaking,Elaine Ferguson.  (2015-02-03)  Complementary feeding recommendations based on locally available foods in Indonesia..  Food and nutrition bulletin,  35  ((4 Suppl)): (S174-S179).  [PMID:25639135]
57. Daisuke Yasuda,Yuki Imura,Satoshi Ishii,Takao Shimizu,Motonao Nakamura.  (2015-02-19)  The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling..  FASEB journal : official publication of the Federation of American Societies for Experimental Biology,  29  ((6)): (2412-2422).  [PMID:25690651]
58. Rohini Sidhu,Hui Jiang,Nicole Y Farhat,Nuria Carrillo-Carrasco,Myra Woolery,Elizabeth Ottinger,Forbes D Porter,Jean E Schaffer,Daniel S Ory,Xuntian Jiang.  (2015-04-14)  A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid..  Journal of lipid research,  56  ((6)): (1222-1233).  [PMID:25866316]
59. Mónica Acevedo,Paola Varleta,Verónica Kramer,Giovanna Valentino,Teresa Quiroga,Carolina Prieto,Jacqueline Para.  (2015-06-20)  Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor..  International journal of endocrinology,  2015  (934681-934681).  [PMID:26089902]
60. Shuai Yang,Xitao Li,Nasui Wang,Guoshu Yin,Shuhua Ma,Yucai Fu,Chiju Wei,Yongsong Chen,Wencan Xu.  (2015-06-28)  GPR109A Expression in the Murine Min6 Pancreatic Beta Cell Line, and Its Relation with Glucose Metabolism and Inflammation..  Annals of clinical and laboratory science,  45  ((3)): (315-322).  [PMID:26116596]
61. Victoria G Pederick,Bart A Eijkelkamp,Stephanie L Begg,Miranda P Ween,Lauren J McAllister,James C Paton,Christopher A McDevitt.  (2015-08-21)  ZnuA and zinc homeostasis in Pseudomonas aeruginosa..  Scientific reports,  (13139-13139).  [PMID:26290475]
62. D L Cooper,J A Carmical,P C Panus,S Harirforoosh.  (2015-11-05)  Formulation and in vitro evaluation of niacin-loaded nanoparticles to reduce prostaglandin mediated vasodilatory flushing..  European review for medical and pharmacological sciences,  19  ((20)): (3977-3988).  [PMID:26531288]
63. Igor Shats,Jason G Williams,Juan Liu,Mikhail V Makarov,Xiaoyue Wu,Fred B Lih,Leesa J Deterding,Chaemin Lim,Xiaojiang Xu,Thomas A Randall,Ethan Lee,Wenling Li,Wei Fan,Jian-Liang Li,Marina Sokolsky,Alexander V Kabanov,Leping Li,Marie E Migaud,Jason W Locasale,Xiaoling Li.  (2020-03-05)  Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway..  Cell metabolism,  31  ((3)): (564-579).  [PMID:32130883]
64. Amanda Rennick,Rabih Kalakeche,Lindsey Seel,Brian Shepler.  (2013-03-26)  Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients..  Pharmacotherapy,  33  ((6)): (683-690).  [PMID:23526664]
65. Amit V Khera,Parin J Patel,Muredach P Reilly,Daniel J Rader.  (2013-08-13)  The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality..  Journal of the American College of Cardiology,  62  ((20)): (1909-1910).  [PMID:23933538]
66. J Sirc,J Hrib,M Vetrik,R Hobzova,A Zak,B Stankova,O Slanar,R Hromadka,V Sandrikova,J Michalek.  (2015-10-09)  The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia..  Physiological research,  64 Suppl 1  (S51-S60).  [PMID:26447595]
67. Zhichao Liu,Qiang Shi,Don Ding,Reagan Kelly,Hong Fang,Weida Tong.  (2011-12-24)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)..  PLoS computational biology,  ((12)): (e1002310-e1002310).  [PMID:22194678]

Solution Calculators